High functioning investigator sites are essential to the delivery of a successful clinical trial. But not all sites seem able to fulfil their study requirements. The critical question is how do you identify sites that are most likely to deliver your study on time, on budget and on specification? Below is an overview of key challenges, solutions, and opportunities related to clinical trial site selection that we recently detailed in our recent Insider's Insight [1]:
Challenges in Clinical Trial Site Selection
Limited Access to Qualified Sites: Finding sites with the necessary infrastructure, experience, and access to patient populations for specific therapeutic areas can be difficult.
Inconsistent Site Performance: Some sites may have excellent recruitment rates but poor data quality or compliance issues, while others may struggle with enrolment.
Regulatory and Ethical Considerations: Regulatory environments vary between regions and countries, affecting how quickly sites can be activated and how trials are conducted.
Geographic Diversity: Trials may need to be conducted across various geographic locations to ensure diverse patient populations, but logistical and communication challenges increase as sites are added in different regions.
Recruitment and Retention Challenges: Even when sites are qualified, recruiting and retaining the right patient population can be difficult, especially in competitive markets or for rare diseases.
Site Readiness and Start-up Delays: A significant amount of time can be lost waiting for sites to be ready, especially when dealing with administrative delays, lack of staff, or delays in ethics approvals.
Technology and Data Management Gaps: Not all sites may have access to or be proficient in the technologies required for modern clinical trials, such as electronic data capture (EDC) systems or remote monitoring tools.
Solutions to Overcome Site Selection Challenges
Data-Driven Site Selection: Use real-world data (RWD) and historical performance metrics to identify high-performing sites with experience in the specific therapeutic area. Leveraging predictive analytics and artificial intelligence (AI) can improve site selection accuracy by forecasting recruitment potential and site performance.
Site feasibility assessments: Conduct thorough site feasibility assessments, including site visits and interviews with key staff, to evaluate their infrastructure, staff expertise, patient population access, and regulatory readiness.
Streamlined regulatory approvals: Work closely with local regulatory authorities and ethics committees early in the process to ensure faster regulatory approvals. Leverage centralised IRB (Institutional Review Board) or ethics committee models where possible to speed up review and approval times.
Patient-centric approach: Engage sites that have established relationships with patient advocacy groups or have access to specific patient registries. This improves recruitment by focusing on patient needs and minimising the barriers to participation.
Technology and training support: Provide sites with the necessary tools, such as EDC platforms, electronic patient-reported outcomes (ePRO) systems, and remote monitoring technologies. Invest in training to ensure site staff can effectively use these technologies, thus improving data quality and reducing errors.
Site relationship management: Develop strong partnerships with sites, providing continuous support and fostering open communication. This includes offering feedback on performance, providing incentives for achieving recruitment targets, and addressing any challenges that arise during the trial.
Utilise hybrid and decentralised trials: Implement decentralised or hybrid trial models that allow some trial procedures (such as patient monitoring or follow-up visits) to be done remotely. This can increase the pool of potential sites and make it easier to recruit diverse populations by reducing the burden on patients and sites.
Centralised site management and oversight: Adopt a centralized management approach for multi-site trials to improve coordination and consistency in trial conduct. Regular monitoring, communication, and real-time access to data help address challenges quickly.
Risk-based monitoring: Implement risk-base monitoring (RBM) strategies to optimise resource allocation. Focusing monitoring efforts on high-risk sites or processes can reduce costs and ensure better compliance and data quality.
Global and Cultural Adaptation: For multinational trials, adapt protocols and materials to fit the cultural and healthcare infrastructure contexts of different regions. Consider language differences, local medical practices, and patient expectations.
Opportunities for Improvement and Innovation
Collaborative networks: Engage in collaborative networks of sites (e.g., Site Management Organizations or SMOs) that have a proven track record of running successful trials. These networks have standardized processes and can help accelerate site identification and start-up.
Precision recruitment using digital tools: Digital search tools can help analyse large datasets to identify optimal sites and predict patient recruitment rates as well as identify underutilised patient populations through social media outreach or direct-to-patient campaigns.
Patient registries and real-world data: Use patient registries and real world data (RWD) sources, such as electronic health records (EHRs) and insurance databases, to identify eligible patients and inform site selection. This can help prioritise sites where patient populations are concentrated, reducing recruitment delays.
Decentralised clinical trials: Expanding decentralised trial models that rely on telemedicine, wearables, and home health services can widen the pool of potential sites and patients. This is especially beneficial in reaching underserved populations or those with mobility limitations.
Global site expansion: Developing countries present untapped opportunities for site expansion. With the right training and infrastructure development, these regions can provide access to new patient populations while maintaining cost-effective site operations.
Enhanced Patient Engagement Tools: Leveraging mobile apps, patient portals, and wearable devices for real-time patient engagement, monitoring, and retention can help sites maintain high levels of participation and protocol adherence.
Conclusion
Site selection, an often underrated and poorly understood discipline. Addressing clinical trial site selection challenges requires a combination of data-driven decision-making, technology adoption, and strategic partnerships. By implementing solutions like data analytics, decentralised trial models, and enhanced site management practices, sponsors and CROs can overcome many of the barriers to site selection. Since poor site selection can have an impact on study delivery (and possibly your short term career prospects) you want to be sure you make the right decisions.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Scientific knowledge should be accessible to all and if you are those communicating science
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
We recently encouraged writers (of all kinds) in our recent Insider’s Insight to experiment with large language.
We all need heroes - people who can champion our cause - helping the world to understand our rationale
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Searching the literature can take various forms, ranging from a quick scan of recent publications
Our team are exploring different and novel ways for young people to enter the pharmaceutical industry.
I have never been great at conferences. People don’t believe me but I am painfully shy and far too worried about what.
I am continually reminded that I must work toward better relationships with my sons than the one I had with my dad.
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
